A Randomized, Double-blind, Vehicle-controlled Multicenter Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ATI-50002 Topical Solution Administered Twice-Daily for 28 Days in Adult Subjects With AU and AT

Trial Profile

A Randomized, Double-blind, Vehicle-controlled Multicenter Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ATI-50002 Topical Solution Administered Twice-Daily for 28 Days in Adult Subjects With AU and AT

Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2017

At a glance

  • Drugs ATI 50002 (Primary)
  • Indications Alopecia areata
  • Focus Adverse reactions
  • Sponsors Aclaris Therapeutics
  • Most Recent Events

    • 07 Nov 2017 According to an Aclaris Therapeutics media release, data is expected to be available in the first half of 2018.
    • 07 Nov 2017 Status changed from not yet recruiting to recruiting, according to an Aclaris Therapeutics media release.
    • 27 Oct 2017 Planned initiation date changed from 23 Oct 2017 to 31 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top